196
Participants
Start Date
December 12, 2021
Primary Completion Date
February 6, 2024
Study Completion Date
February 28, 2024
Rilzabrutinib
Pharmaceutical form: Tablet Route of administration: Oral
placebo
Pharmaceutical form: Tablet Route of administration: Oral
Investigational Site Number : 1000002, Sofia
Investigational Site Number : 1000004, Kozloduy
Investigational Site Number : 3480001, Edelény
Investigational Site Number : 3480004, Hajdunánás
Investigational Site Number : 1000003, Sevlievo
Investigational Site Number : 1000001, Rousse
Investigational Site Number : 3480003, Pécs
Investigational Site Number : 6160005, Bialystok
Investigational Site Number : 7240003, Madrid / Madrid
Investigational Site Number : 7240001, Málaga
Investigational Site Number : 7920001, Mersin
Investigational Site Number : 4840003, Durango
Investigational Site Number : 7920002, Istanbul
Investigational Site Number : 7240004, Santander
Investigational Site Number : 6420001, Düsseldorf
Investigational Site Number : 4840001, Guadalajara
Investigational Site Number : 4840002, Monterrey
Investigational Site Number : 4840005, San Juan del Río
Investigational Site Number : 6160001, Lodz
Investigational Site Number : 4840004, Veracruz
Investigational Site Number : 6420002, Cluj-Napoca
Investigational Site Number : 1520006, Quillota
Investigational Site Number : 1520005, Curicó
Investigational Site Number : 1520001, Santiago
Investigational Site Number : 1520004, Santiago
Investigational Site Number : 1520007, Santaigo
Investigational Site Number : 1520003, Santiago
Investigational Site Number : 0320004, Berazategui
Investigational Site Number : 0320006, CABA
Investigational Site Number : 0320003, CABA
Investigational Site Number : 0320001, Buenos Aires
Investigational Site Number : 0320005, Ciudad Autonoma Buenos Aires
Investigational Site Number : 0320002, Ciudad Autonoma Buenos Aires
Investigational Site Number : 1240006, Vancouver
Investigational Site Number : 1240005, Waterloo
Investigational Site Number : 1520002, Talca
Investigational Site Number : 6160009, Poznan
Investigational Site Number : 6160007, Lublin
Investigational Site Number : 6160003, Bialystok
Investigational Site Number : 6160006, Gdansk
Investigational Site Number : 6160002, Krakow
Investigational Site Number : 6160010, Lodz
Investigational Site Number : 6160008, Ostrowiec Świętokrzyski
Investigational Site Number : 4100007, Daegu
Investigational Site Number : 4100004, Seoul
Investigational Site Number : 4100005, Seoul
Investigational Site Number : 4100002, Seoul
Investigational Site Number : 4100006, Seoul
Investigational Site Number : 4100001, Seoul
Investigational Site Number : 8260002, Cambridge
Investigational Site Number : 8260001, Bradford
Lead Sponsor
Sanofi
INDUSTRY